Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781668 | 1.00 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL5115328 | 0.99 | CHRNB2 (0.43) | CHRNB2CHRNA4 | |
| SCHEMBL3259832 | 0.76 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL4642420 | 0.76 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL4646597 | 0.76 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL3136032 | 0.76 | CHRNB2 (0.50) | CHRNB2CHRNA4 | |
| SCHEMBL3257091 | 0.75 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL3151406 | 0.75 | CHRNB1 (0.51) | CHRNB2 | |
| Hydrochloric Acid SCHEMBL5105093 | 0.75 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL5103359 | 0.75 | CHRNB2 (0.51) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748043-B1 | Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2008-08-20 | — | — | EP | claimed |
| US-7348344-B2 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-03-25 | — | — | US | claimed |
| US-20070027191-A1 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | claimed |
| EP-1748043-A1 | Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2007-01-31 | — | — | EP | claimed |
| EP-1979321-B9 | NOVEL PYRIDINYLAMINOALKYLENE- AND PYRIDINYLOXYALKYLENE-CYCLOPROPANAMINES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2010-02-17 | — | — | EP | disclosed |
| EP-1979321-B1 | NOVEL PYRIDINYLAMINOALKYLENE- AND PYRIDINYLOXYALKYLENE-CYCLOPROPANAMINES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2009-07-29 | — | — | EP | disclosed |
| EP-1748043-B1 | Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-7348344-B2 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-03-25 | — | — | US | disclosed |
| EP-1748043-A1 | Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, process for their préparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027191-A1 | Polysubstituted 1,1-pyridyloxycyclopropanamine compounds | CHRM1, CHRNA1, CHRNA9 | CHRNB2 22/4885CHRNA4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.